Role of farnesoid X receptor (FXR) in the process of differentiation of bone marrow stromal cells into osteoblasts

Bone

Volumn 49, Issue 6, 2011, Pages 1219-1231

  Id Boufker, Hichame ^a   Lagneaux, Laurence ^a   Fayyad Kazan, Hussein ^a   Badran, Bassam ^a   Najar, Mehdi ^a   Wiedig, Murielle ^a   Ghanem, Ghanem ^a   Laurent, Guy ^b   Body, Jean Jacques ^c   Journé, Fabrice ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY OF MONS   (Belgium)

^c BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Bile acids; Bisphosphonates; Bone marrow stromal cells; Farnesoid X receptor; Osteoblasts

Indexed keywords

ADIPONECTIN; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; BONE SIALOPROTEIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CHENODEOXYCHOLIC ACID; FARNESOID X RECEPTOR; FARNESOL; GUGGULSTERONE; IBANDRONIC ACID; LEPTIN; OSTEOCALCIN; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR RUNX2; ZOLEDRONIC ACID;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW CELL; CALCIFICATION; CELL DIFFERENTIATION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID VESICLE; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PRENYLATION; STROMA CELL; TRANSCRIPTION INITIATION;

ADOLESCENT; ADULT; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE MARROW CELLS; BONE MATRIX; CALCIFICATION, PHYSIOLOGIC; CALCIUM; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DIPHOSPHONATES; DNA; GENE EXPRESSION REGULATION; GENE SILENCING; HUMANS; OSTEOBLASTS; PREGNENEDIONES; PROTEIN BINDING; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; STROMAL CELLS; YOUNG ADULT;

EID: 81355127623     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.08.013     Document Type: Article

References (55)

1. Body J.J. Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis. Bone 2002, 30:75S-79S.
2. Roodman G.D., Windle J.J. Paget disease of bone. J Clin Invest 2005, 115:200-208.
3. Clines G.A., Guise T.A. Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 2008, 10:e7.
4. Atkins G.J., Kostakis P., Pan B., Farrugia A., Gronthos S., Evdokiou A., et al. RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res 2003, 18:1088-1098.
5. Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Yano K., et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998, 253:395-400.
6. Ecarot-Charrier B., Glorieux F.H., van der Rest M., Pereira G. Osteoblasts isolated from mouse calvaria initiate matrix mineralization in culture. J Cell Biol 1983, 96:639-643.
7. Silva J., Dasgupta S., Wang G., Krishnamurthy K., Ritter E., Bieberich E. Lipids isolated from bone induce the migration of human breast cancer cells. J Lipid Res 2006, 47:724-733.
8. Parks D.J., Blanchard S.G., Bledsoe R.K., Chandra G., Consler T.G., Kliewer S.A., et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999, 284:1365-1368.
9. Modica S., Moschetta A. Nuclear bile acid receptor FXR as pharmacological target: are we there yet?. FEBS Lett 2006, 580:5492-5499.
10. Forman B.M., Goode E., Chen J., Oro A.E., Bradley D.J., Perlmann T., et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995, 81:687-693.
11. Makishima M., Okamoto A.Y., Repa J.J., Tu H., Learned R.M., Luk A., et al. Identification of a nuclear receptor for bile acids. Science 1999, 284:1362-1365.
12. Edwards P.A., Kast H.R., Anisfeld A.M. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J Lipid Res 2002, 43:2-12.
13. Sinal C.J., Tohkin M., Miyata M., Ward J.M., Lambert G., Gonzalez F.J. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000, 102:731-744.
14. Claudel T., Staels B., Kuipers F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 2005, 25:2020-2030.
15. Lee F.Y., Lee H., Hubbert M.L., Edwards P.A., Zhang Y. FXR, a multipurpose nuclear receptor. Trends Biochem Sci 2006, 31:572-580.
16. Body J.J. Bisphosphonates for malignancy-related bone disease: current status, future developments. Support Care Cancer 2006, 14:408-418.
17. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13:581-589.
18. Russell R.G. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007, 119(Suppl 2):S150-S162.
19. Benford H.L., Frith J.C., Auriola S., Monkkonen J., Rogers M.J. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999, 56:131-140.
20. Orriss I.R., Key M.L., Colston K.W., Arnett T.R. Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem 2009, 106:109-118.
21. Xiong Y., Yang H.J., Feng J., Shi Z.L., Wu L.D. Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells. J Int Med Res 2009, 37:407-416.
22. Cui J., Huang L., Zhao A., Lew J.L., Yu J., Sahoo S., et al. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J Biol Chem 2003, 278:10214-10220.
23. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
24. Murray E., Provvedini D., Curran D., Catherwood B., Sussman H., Manolagas S. Characterization of a human osteoblastic osteosarcoma cell line (SAOS-2) with high bone alkaline phosphatase activity. J Bone Miner Res 1987, 2:231-238.
25. Yang J.Y., Jung J.Y., Cho S.W., Choi H.J., Kim S.W., Kim S.Y., et al. Chloride intracellular channel 1 regulates osteoblast differentiation. Bone 2009, 45:1175-1185.
26. Devleeschouwer N., Legros N., Olea-Serrano N., Paridaens R., Leclercq G. Estrogen conjugates and serum factors mediating the estrogenic trophic effect on MCF-7 cell growth. Cancer Res 1987, 47:5883-5887.
27. Justesen J., Pedersen S.B., Stenderup K., Kassem M. Subcutaneous adipocytes can differentiate into bone-forming cells in vitro and in vivo. Tissue Eng 2004, 10:381-391.
28. Kim I.S., Song Y.M., Cho T.H., Park Y.D., Lee K.B., Noh I., et al. In vitro response of primary human bone marrow stromal cells to recombinant human bone morphogenic protein-2 in the early and late stages of osteoblast differentiation. Dev Growth Differ 2008, 50:553-564.
29. Meloan S.N., Puchtler H., Valentine L.S. Alkaline and acid alizarin red S stains for alkali-soluble and alkali-insoluble calcium deposits. Arch Pathol 1972, 93:190-197.
30. Id Boufker H, Lagneaux L, Najar M, Piccart M, Ghanem G, Body JJ, Journe F. The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. BMC Cancer 10: 298.
31. Tondreau T., Lagneaux L., Dejeneffe M., Delforge A., Massy M., Mortier C., et al. Isolation of BM mesenchymal stem cells by plastic adhesion or negative selection: phenotype, proliferation kinetics and differentiation potential. Cytotherapy 2004, 6:372-379.
32. Journe F., Kheddoumi N., Chaboteaux C., Duvillier H., Laurent G., Body J.J. Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells. Breast Cancer Res 2008, 10:R4.
33. Badran B.M., Kunstman K., Stanton J., Moschitta M., Zerghe A., Akl H., et al. Transcriptional regulation of the human CD3 gamma gene: the TATA-less CD3 gamma promoter functions via an initiator and contiguous Sp-binding elements. J Immunol 2005, 174:6238-6249.
34. Pineda Torra I., Claudel T., Duval C., Kosykh V., Fruchart J.C., Staels B. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 2003, 17:259-272.
35. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003, 9:2643-2658.
36. Bauer D.C. HMG CoA reductase inhibitors and the skeleton: a comprehensive review. Osteoporos Int 2003, 14:273-282.
37. Lew J.L., Zhao A., Yu J., Huang L., De Pedro N., Pelaez F., et al. The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion. J Biol Chem 2004, 279:8856-8861.
38. Journe F., Laurent G., Chaboteaux C., Nonclercq D., Durbecq V., Larsimont D., et al. Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation. Breast Cancer Res Treat 2008, 107:49-61.
39. Shui C., Spelsberg T.C., Riggs B.L., Khosla S. Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. J Bone Miner Res 2003, 18:213-221.
40. Chou M.Y., Yan D., Jafarov T., Everett E.T. Modulation of murine bone marrow-derived CFU-F and CFU-OB by in vivo bisphosphonate and fluoride treatments. Orthod Craniofac Res 2009, 12:141-147.
41. Im G.I., Qureshi S.A., Kenney J., Rubash H.E., Shanbhag A.S. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 2004, 25:4105-4115.
42. Fu L., Tang T., Miao Y., Zhang S., Qu Z., Dai K. Stimulation of osteogenic differentiation and inhibition of adipogenic differentiation in bone marrow stromal cells by alendronate via ERK and JNK activation. Bone 2008, 43:40-47.
43. Ebert R., Zeck S., Krug R., Meissner-Weigl J., Schneider D., Seefried L., et al. Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation. Bone 2009, 44:858-864.
44. Tenta R., Pitulis N., Tiblalexi D., Consoulas C., Katopodis H., Konstantinidou E., et al. Mechanisms of the action of zoledronic acid on human MG-63 osteosarcoma cells. Horm Metab Res 2008, 40:737-745.
45. Idris A.I., Rojas J., Greig I.R., Van't Hof R.J., Ralston S.H. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 2008, 82:191-201.
46. Rizzo G., Disante M., Mencarelli A., Renga B., Gioiello A., Pellicciari R., et al. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol 2006, 70:1164-1173.
47. Cariou B., van Harmelen K., Duran-Sandoval D., van Dijk T.H., Grefhorst A., Abdelkarim M., et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 2006, 281:11039-11049.
48. Abdelkarim M, Caron S, Duhem C, Prawitt J, Dumont J, Lucas A, Bouchaert E, Briand O, Brozek J, Kuipers F, Fievet C, Cariou B, Staels B. The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways. J Biol Chem 285: 36759-36767.
49. Wu J., Xia C., Meier J., Li S., Hu X., Lala D.S. The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptor. Mol Endocrinol 2002, 16:1590-1597.
50. Ulbricht C., Basch E., Szapary P., Hammerness P., Axentsev S., Boon H., et al. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement Ther Med 2005, 13:279-290.
51. Sinal C.J., Gonzalez F.J. Guggulsterone: an old approach to a new problem. Trends Endocrinol Metab 2002, 13:275-276.
52. Urizar N.L., Liverman A.B., Dodds D.T., Silva F.V., Ordentlich P., Yan Y., et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 2002, 296:1703-1706.
53. Yu B.Z., Kaimal R., Bai S., El Sayed K.A., Tatulian S.A., Apitz R.J., et al. Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia. J Nat Prod 2009, 72:24-28.
54. Owsley E., Chiang J.Y. Guggulsterone antagonizes farnesoid X receptor induction of bile salt export pump but activates pregnane X receptor to inhibit cholesterol 7alpha-hydroxylase gene. Biochem Biophys Res Commun 2003, 304:191-195.
55. Brobst D.E., Ding X., Creech K.L., Goodwin B., Kelley B., Staudinger J.L. Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor. J Pharmacol Exp Ther 2004, 310:528-535.